



6-7 March  
**2024**

Congress Center  
Basel | Switzerland



# 8<sup>th</sup> AMR Conference

**Novel Antimicrobials & AMR Diagnostics**

**[amr-conference.com](https://amr-conference.com)**  
**#AMRconference**

Organization: bamconn GmbH | Erholungsweg 51 | 13509 Berlin  
Boris Mannhardt | [info@bamconn.eu](mailto:info@bamconn.eu) | Tel. +49 (0)176 101 439 86

**bamconn**



**SSID: Free-Messe-Basel**  
Free SMS Login (one login for each device)

## About the AMR Conference

The #AMRconference is a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss **strategies and specific challenges faced by the innovation ecosystem** in bringing new antimicrobial treatments and diagnostics to the market.

The conference is the one-stop shop to catch up with the latest trends in the development of AMR products, by covering **scientific, regulatory, financial and policy topics**. Besides high-level talks, the conference is a great place to network and exchange views on innovative technologies, development paths and alternative business models with your peers. The conference also offers a **one-to-one partnering** to facilitate interactions.

Once more, the 8<sup>th</sup> edition will cover the whole innovation value chain, including scientific breakthrough, preclinical and clinical development, but also financial topics such as public funding for R&D, market incentive and investors' perspective. Specific sessions will also be dedicated to **phage therapy, diagnostics, antifungals and anti-tuberculosis drug combinations**. There will also be a special focus on **One Health** and on how **artificial intelligence** can foster prevention and smart use of antibiotics. Among other highlights are a **start-up pitch**, hosted by the pharma-backed incubator INCATE, and a **presentation of scientific posters**.

The AMR Conference is jointly organized by BEAM Alliance and bamconn GmbH. It was started in 2017 as part of the annual "Berlin Conference on Life Sciences" series which was established twelve years ago as an event format to discuss the challenges of SME-driven innovation for the health market and to **offer a platform for meeting experts from business, science, clinics, finance, regulatory affairs and intellectual property**.

**The BEAM Alliance** is one of the major supporting partners of the AMR Conference. Launched in June 2015, the BEAM (Biotech companies in Europe combating AntiMicrobial Resistance) Alliance gathers more than 70 small and medium-sized European biotech and diagnostics companies committed to developing innovative products for fending off antibiotic-resistant pathogens. BEAM Alliance carries the voice of SMEs to support policies and incentives in antimicrobial research and development in Europe.

**bamconn GmbH** was established in November 2022 as a spin-off of BIOCUM AG and continues its entire event management as an independent company. It is built on more than 15 years of experience in the planning, organization and implementation of scientific events and exhibitions. The portfolio covers the entire spectrum from small workshops with 20 participants to multi-day international conferences for up to 2,000 people as well as exhibitions on the topic of bioeconomy throughout Europe. Customers for whom the bamconn team worked so far are companies, research institutions, associations and federal ministries as well as subordinate authorities and EU-funded projects.

# At a glance

## Conference Day 1 • 6 March 2024

09:00 - 11:00	<b>BEAM Alliance General Assembly</b> (BEAM members only) <b>Room Kairo</b> page 6		
09:30 - 11:00	<b>Pre-conference workshop</b> “Milestone-driven R&D – opportunities and challenges” <b>Room Shanghai</b> page 6		
10:00 - 19:00	<b>1-to-1 Partnering Meetings</b>		
10:00 - 19:30	Poster presentations and exhibition open		
11:30 - 13:00	<b>Opening Session</b> 2024, a decisive year – update on the AMR environment <b>Room Shanghai</b> page 6		
13:00 - 13:15	<b>Announcement of new CARB-X funding rounds</b> <b>Room Shanghai</b> page 6		
13:15 - 14:00	Lunch break   poster presentation & exhibition		
14:00 - 15:30	<b>Parallel Sessions</b>		
	<b>Taking actions on pull incentives</b> <b>Room Shanghai</b> page 7	<b>Preclinical models to optimize translation to human</b> <b>Room Delhi</b> page 7	<b>Vaccines to keep AMR at bay</b> <b>Room Kairo</b> page 7
15:30 - 16:00	Networking break   poster session & exhibition		
16:00 - 17:30	<b>Parallel Sessions</b>		
	<b>Meaningful clinical trials: combining regulatory and clinical differentiation needs</b> <b>Room Shanghai</b> page 8	<b>Novel disruptive approaches to fight AMR</b> <b>Room Delhi</b> page 8	<b>How can AI foster prevention and smart use of antibiotics in a One Health world?</b> <b>Room Kairo</b> page 8
17:30 - 18:00	Networking break   poster session & exhibition		
18:00 - 19:30	<b>Start-up pitch</b> <b>Room Shanghai</b> page 9		
19:30 - 21:30	Reception in the exhibition hall		

Day 1  
6 Mar.

# Conference Day 2 • 7 March 2024

08:00 - 18:30 Registration, poster presentations and exhibition open

08:30 - 18:00 **1-to-1 Partnering Meetings**

08:30 - 09:30 **Plenary Session**

**A phage cocktail for breakfast?**

**Room Shanghai** page 10

09:30 - 10:00 Networking break | poster presentation & exhibition

10:00 - 11:30 **Parallel Sessions**

**Making the case for investing in AMR R&D**

**Room Shanghai** page 10

**Tuberculosis: new tools against an old enemy**

**Room Delhi** page 10

**New tricks to combat fungal infections**

**Room Kairo** page 10

11:30 - 13:00 Lunch break | poster presentation & exhibition

13:00 - 14:30 **Parallel Sessions**

**Push funding: a lifeline for R&D**

**Room Shanghai** page 11

**Fast, reliable and cost-effective diagnostics**

**Room Delhi** page 11

**The true value of anti-microbial products**

**Room Kairo** page 11

14:30 - 15:00 Networking break | poster presentation & exhibition

15:00 - 16:30 **Parallel Sessions**

**Greatest reach to the greatest need**

**Room Shanghai** page 12

**Leveraging the power of diagnostics in clinical practice**

**Room Delhi** page 12

**Technology update**

**Room Kairo** page 12

16:30 - 17:00 Coffee break with poster session & exhibition

17:00 - 18:00 **Closing Session**

**Multisectoral response to a multisectoral challenge**

**Room Shanghai** page 12

18:00 - 19:00 Farewell reception in the exhibition hall

**Day 2**  
**7 Mar.**

# Pre-conference

Room Kairo

09:00 - 11:00 **BEAM Alliance General Assembly**  
for BEAM members only



Room Shanghai

09:30 - 11:00 Pre-conference workshop  
**Milestone-driven R&D – opportunities and challenges**  
jointly organized by



**CARB-X**  
Combating Antibiotic-Resistant Bacteria

**GARDP**  
Global Antibiotic Research and Development Partnership

**jpiamr**  
Joint Programming Initiative in Antimicrobial Research

**repair**  
Impact Fund  
New Technology



Introduction

*Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna, Austria*

Integrating TPPs and TCPs in discovery strategies

*Malcolm Page, Antibiotic Research*

Data-driven decision making in antibiotics preclinical research

*Kenneth Bradley, F. Hoffmann-La Roche Ltd*

Discussion

Day 1  
6 Mar.

## Opening Session

Room Shanghai

11:30 - 13:00 **2024, a decisive year - update on the AMR environment**

*Marc Gitzinger, BioVersys AG & BEAM Alliance*

*Judith Moore, World Economic Forum*

*Alexandra Cameron, World Health Organization*

*Wolfgang Philipp, European Commission DG HERA*

*Jonathan Pearce, Antibiotic Research UK*

*Zoe Molyneux, Wellcome Trust*

*Alan Donnelly, G20 Health & Development Partnership*

Room Shanghai

13:00 - 13:15 **Announcement of the new CARB-X funding rounds**

Themes and timelines of the  
new CARB-X funding rounds

hosted by



*Erin Duffy, CARB-X*

## Parallel Sessions

### Room Shanghai

---

#### 14:00 - 15:30 **Taking actions on pull incentives**

---

*Kevin Outterson, Boston University & CARB-X*

---

*Pierre Dubois, Toulouse School of Economics*

---

*Damiët Onderstal, European Commission DG HERA*

---

*Pietro Erba, European Commission DG SANTE*

---

*further speakers to be confirmed*

---

### Room Delhi

---

#### 14:00 - 15:30 **Preclinical models to optimize translation to human**

---

*Martin Everett, Aurobac Therapeutics*

---

*Ian Morrissey, Antimicrobial Focus Ltd*

---

*Caterina Bissantz, F. Hoffmann-La Roche Ltd*

---

*Coen van Hasselt, Leiden University*

---

*Christopher Darlow, Liverpool University*

---

*Markus Zeitlinger, Medical University of Vienna*

---

*Nicolas Tesse, Septeos*

---

**Day 1**  
6 Mar.

### Room Kairo

---

#### 14:00 - 15:30 **Vaccines to keep AMR at bay**

---

*Marianne Holm, Novo Nordisk Foundation*

---

*Ed Buurman, CARB-X*

---

*Ramanan Laxminarayan, One Health Trust*

---

*Patricia Martin, LimmaTech Biologics AG*

---

*Laura Plant, International Vaccine Institute*

---

*Mateusz Hasso-Agopsowicz, World Health Organization*

---

## Parallel Sessions

### Room Shanghai

---

**16:00 - 17:30** **Meaningful clinical trials: combining regulatory and clinical differentiation needs**

---

*Glenn Dale, BioVersys AG*

---

*Radu Botgros, European Medicines Agency*

---

*Mark Jones, Basilea Pharmaceutica International Ltd*

---

*Ulrich Granzer, Granzer Regulatory Services GmbH*

---

*David Paterson, National University of Singapore*

---

### Room Delhi

---

**16:00 - 17:30** **Novel disruptive approaches to fight AMR**

---

hosted by  **NCCR  
AntiResist**

---

*Christoph Dehio, NCCR AntiResist*

---

*Maximiliano G. Gutierrez, Francis Crick Institute*

---

*Lucas Boeck, University of Basel*

---

*Claudia Zampaloni, F. Hoffmann-La Roche Ltd*

---

**Day 1**  
6 Mar.

### Room Kairo

---

**16:00 - 17:30** **How can AI foster prevention and smart use of antibiotics in a One Health world?**

---

supported by  **GLOBAL  
AMR R&D  
HUB**

---

*Lothar Wieler, Hasso Plattner Institute*

---

*Ralf Sudbrak, Global AMR R&D Hub*

---

*Ramanan Laxminarayan, One Health Trust*

---

*Lara Urban, Helmholtz Munich*

---

*Thomas van Boeckel, ETH Zurich*

---

*Muna Abu-Sin, Robert Koch Institute*

---



18:00–19:30 **Start-up pitch**

hosted by 

Prize sponsor 

---

***Douglas Häggström, INCATE***

---

*Running order of pitching companies:*

***TabriX***, presented by Marc Creus

---

***BrlgID Biologics***, presented by Soumya Palliyil

---

***BamA Inhibitor***, presented by Till Schäberle

---

***Microplate Dx***, presented by Stuart Hannah

---

***Omnicin Therapeutics***, presented by Auke van Heel

---

***Obulytix***, presented by Yves Briers

---

***Tolka AI Therapeutics***, presented by Johan Wikstrom

---

***Generare***, presented by Guillaume Vandenesch

---

***Theralia AB***, presented by Baris Ata Borsa

---

***Puray***, presented by Martin Duffner

---

***Smartbax***, presented by Robert Macsics

---

**Day 1**  
6 Mar.

## Plenary Session

Room Shanghai

### 08:30 - 09:30 **A phage cocktail for breakfast?**

*Valeria Gigante, World Health Organization*

*Mercedes Gonzalez Moreno, INCATE*

*Alexander Belcredi, BioNTech R&D (Austria) GmbH*

*Thilo Köhler, University of Geneva*

*Shawna McCallin, Balgrist University Hospital Zurich*

## Parallel Sessions

Room Shanghai

### 10:00 - 11:30 **Making the case for investing in AMR R&D**

*Marie Petit, Villiger Valuation*

*Carly Levine, AMR Action Fund*

*Marc Lemonnier, Antabio*

*further speakers to be confirmed*

**Day 2**  
7 Mar.

Room Delhi

### 10:00 - 11:30 **Tuberculosis: new tools against an old enemy**

*Suvanand Sahu, STOP TB Partnership*

*Claire Jordan Brooks, University Carlos III Madrid*

*Hoon Sang Lee, RIGHT Foundation*

*Fuad Mirzayev, World Health Organization*

*Nelly Badalato, Genoscreen*

Room Kairo

### 10:00 - 11:30 **New tricks to combat fungal infections**

*Mark Jones, Basilea Pharmaceutica International Ltd*

*Dionysios Neofytos, University Hospitals Geneva*

*Nina Khanna, University Hospital Basel*

*Mai Hoang, Dynamic42 GmbH*

*Mark Jones, Basilea Pharmaceutica International Ltd*

## Parallel Sessions

### Room Shanghai

#### 13:00 - 14:30 Push funding: a lifeline for R&D

*Remko van Leeuwen, SurvivX*

*Dennis M. Dixon, NIAID, US National Institutes of Health*

*Clive Mason, LifeArc*

*Laura Marin, Joint Programming Initiative on Antimicrobial Resistance*

*Alessandra Martini, European Commission DG RTD*

*Jean-Baptiste Perrin, European Commission DG HERA*

*Damiano de Felice, CARB-X*

### Room Delhi

#### 13:00 - 14:30 Fast, reliable and cost-effective diagnostics

hosted by



*Jens Hellwege, InfectoGnostics Research Campus Jena*

*Milovan Stankov-Pugès, NG Biotech*

*Adrian Egli, University of Zurich*

*Rafael Cantón, Ramon y Cajal Hospital*

*Eva Rennen, Nostics*

*Surbhi Malhotra, University of Antwerp*

*Betsy Wonderly Trainor, CARB-X*

**Day 2**  
**7 Mar.**

### Room Kairo

#### 13:00 - 14:30 The true value of antimicrobial products

hosted by



*Deepali Patel, AMR Action Fund*

*Jennifer Quinn, Debiopharm International SA*

*Michele Cecchini, OECD*

*Sophie Cooper, UK National Institute for Health and Care Excellence (NICE)*

*Pierre Dubois, Toulouse School of Economics*

*Rachel Freeman, IQVIA*

*Maria Larsson Ortino, Legal & General Investment Management*

## Parallel Sessions

### Room Shanghai

---

#### 15:00 - 16:30 **Greatest reach to the greatest need**

---

*Jennifer Cohn, GARDP*

*Alexandra Cameron, World Health Organization*

*Mirfin Mpundu, ReAct Africa*

*Michael Anderson, MedAccess*

*Yann Ferrisse, GARDP*

*Brenda Waning, STOP TB Partnership*

*Olivier Menzel, Swiss Agency for Development and Co-Operation*

---

### Room Dehli

---

#### 15:00 - 16:30 **Leveraging the power of diagnostics in clinical practice**

---

*Till Bachmann, University of Edinburgh*

*Gail Hayward, University of Oxford*

*Maarten Postma, University of Groningen*

*Magda Rosenmüller, IESE Business School*

*Gemma Johnson, OLM Diagnostics*

*Toby Leslie, The Fleming Fund*

---

### Room Kairo

---

#### 15:00 - 16:30 **Technology update**

---

*Peter Jackson, Infex Therapeutics Ltd*

*Susana Tomásio, Collaborative Drug Discovery*

*John Cadwell, FiberCell Systems Inc.*

*Hee-Jong Hwang, A&J Science*

*Matti Jalasvuori, PrecisionPhage Oy*

*Colm Leonard, Infex Therapeutics Ltd*

---

## Closing Session

### Room Shanghai

---

#### 17:00 - 18:00 **Multisectoral response to a multisectoral challenge**

---

*Florence Séjourné, Aurobac Therapeutics*

*Cary Adams, Union for International Cancer Control*

*Pratik Bhatnagar, IQVIA*

*Mark Albrecht, US Department of Health and Human Services*

*Aanika Dalal, Alliance for Reducing Microbial Resistance (ARMoR)*

---


# Exhibitors


Booth	Exhibitor	
# 1	Collaborative Drug Discovery Inc.	
# 2	Centre for Process Innovation Ltd	
# 3	Cerdak (Pty) Ltd	
# 4	Infex Therapeutics Ltd	
# 5	BioVersys AG	
# 6	Leibniz Health Technologies	
# 7	Infectognostics Research Campus Jena e.V.	
# 8	IMI AMR Accelerator	
# 9	German Center for Infection Research e.V.	
# 10	INCATE	
# 11	WuXi AppTec	
# 12	Aurobac Therapeutics SAS	
# 13	bioMérieux S.A.	
# 14	Resistell AG	
# 15	Basilea Pharmaceutica International Ltd	
# 16	Global Antibiotic Research & Development Partnership	
# 17	Asymchem Inc.	
# 18	PrecisionPhage Ltd	
# 19	Selvita S.A.	
# 20	FiberCell Systems Inc. / Bio-Connect	
# 21	Rime Bioinformatics SAS	
# 22	Symcel AB	
# 23	Epithelix Sàrl	

# Floor Map

## Venue:

Congress Center Basel  
Hall 4  
Messeplatz 21  
4058 Basel, Switzerland





- Program Rooms
- Exhibitor Booths
- Catering
- Meeting Room Innovate UK
- Partnering Area
- Poster Exhibition

## Poster Exhibition

No.	Title	Corresponding Author
1	<b>Bacterial Impedance Cytometry (BIC) - Gaining insights into bacterial responses to antimicrobials</b>	<b>Lucy Bock</b> , UK Health Security Agency
2	<b>Microfluidic platform to visualize and quantify bacterial response to dynamic drug treatments</b>	<b>Friederike Born</b> , ETH Zurich
3	<b>An anti-virulence strategy to treat Salmonella infections: Development of lead compounds targeting the transcriptional regulator HlID</b>	<b>Hakim Boudrioua</b> , University Hospital Tubingen
4	<b>A VersaTile-driven, AI-augmented platform for the development of customized phage lysin-based antibiotics</b>	<b>Yves Briers</b> , Ghent University
5	<b>Phage development for clinical applications</b>	<b>Karine Charton</b> , Phaxiam Therapeutics S.A.
6	<b>Mechanism of action studies using systematic analysis platform</b>	<b>Jan-Martin Daniel</b> , University of Bonn
7	<b>HoloMoA: Combination of time-lapse quantitative phase imaging with deep learning for rapidly detecting the Mechanism of Action of an antimicrobial and its potential novelty</b>	<b>Sophie Dixneuf</b> , BIOASTER
8	<b>Decoding polymicrobial interactions in catheter-associated urinary tract infections</b>	<b>Ashim Dubey</b> , Ecole Polytechnique federale de Lausanne
9	<b>Faecal Microbiota Transplantation, a novel treatment to tackle Antimicrobial Resistance in Chronic Liver Disease – induces phage network remodeling and enteric pathogen reduction, enhances intestinal barrier function and immunometabolism, altering mucosal IL-17 immunity</b>	<b>Lindsey Edwards</b> , King's College London
10	<b>Novel AI platform for antimicrobial drug discovery</b>	<b>Yojana Gadiya</b> , Fraunhofer ITMP ScreeningPort
11	<b>DCB001: a new precision antibiotic candidate against MRSA</b>	<b>Juan Garcia-Sanchez</b> , Université Côte d'Azur
12	<b>Metabolism-guided optimization of next-generation benzothiazinones towards highly potent antituberculosis agents</b>	<b>Sina Gerbach</b> , Leibniz Institute for Natural Product Research and Infection Biology
13	<b>Inhibition and eradication of Pseudomonas aeruginosa biofilms by secondary metabolites of Nocardopsis lucentensis EMB25</b>	<b>Nikky Goel</b> , IIT DELHI
14	<b>Dual mode of Action Broad-spectrum Bacterial Gyrase Inhibition by the Peptide Antibiotic Albicidin</b>	<b>Frank Gombert</b> , Selmod GmbH
15	<b>Disperazol: treating Pseudomonas aeruginosa catheter associated urinary tract biofilm infections</b>	<b>Michael Graz</b> , Biophys Ltd
16	<b>Invasive aspergillosis-on-chip: A quantitative treatment study of human Aspergillus fumigatus infection</b>	<b>Mai Hoang</b> , Dynamic42 GmbH



No.	Title	Corresponding Author
17	<b>SimCells: genome-free bacterial cells as vaccines against Pseudomonas aeruginosa infections</b>	Jane Hsu, Oxford SimCell Ltd
18	<b>Modeling of intravenous caspofungin administration using an intestine-on-chip reveals altered Candida albicans microcolonies and pathogenicity</b>	Tim Kaden, Dynamic42 GmbH
19	<b>Utilising optical electrophysiology for rapid antimicrobial susceptibility testing to enhance bloodstream infections and sepsis management</b>	Magdalena Karlikowska, Cytecom Ltd.
20	<b>The COMBINE Preclinical Bacterial Strain Repository - A new resource for preclinical lung infection models to assess antibiotic efficacy</b>	Bernhard Kerscher, Paul-Ehrlich-Institute
21	<b>New rapid detection of beta-lactamase producing bacteria using fluorogenic probes</b>	Anne Khoschnud, Molsid S.A.S.
22	<b>Intracellular growth and persistence of Pseudomonas aeruginosa in a lung tissue model</b>	Luisa Lauer, University of Basel
23	<b>Paride - a new Pseudomonas aeruginosa phage</b>	Enea Maffei, ETH Zurich
24	<b>Identification of new antimicrobial resistance genes in E. coli through network diffusion</b>	Anis Mansouri, University of Bologna
25	<b>Empowering Antibiotics in the AMR Landscape: Insights from Dendrimer Conjugation in ALI systems</b>	Laura Martinenghi, Copenhagen University
26	<b>The DSMZ bacteriophage collection and its relevance for fighting antimicrobial resistance</b>	Filipa Martins, DSMZ-German Collection of Microorganisms and Cell Cultures GmbH
27	<b>An MD simulation-enhanced machine learning virtual screening for permeability and accumulation of antimicrobials</b>	Stefan Milenkovic, University of Cagliari, Physics Department
28	<b>Facilitating Phage Applications in Africa and Asia</b>	Tobi Nagel, Phages for Global Health
29	<b>Dimercaptosuccinic acid in combination with carbapenems against strains of Pseudomonas aeruginosa and Acinetobacter baumannii producing metallo-<math>\beta</math>-lactamase in a murine peritonitis model</b>	Patrice Nordmann, Université de Fribourg
30	<b>Novel antibiotic peptides in the fight against AMR</b>	Marit Otterlei, Norwegian University Of Science and Technology
31	<b>Proteomics: Revolution in bacteria identification and AMR detection in one</b>	Armand Paauw, Netherlands Organization for Applied Scientific Research TNO
32	<b>Human bladder microtissue model to study chronic and recurrent UTIs</b>	Gauri Paduthol, Ecole Polytechnique federale de Lausanne
33	<b>Human monoclonal antibodies targeting novel, fungal cell wall proteins offer superior therapeutic efficacy in a preclinical model of infection</b>	Soumya Palliyil, University of Aberdeen
34	<b>Chemistry Center for Combating Antibiotic Resistant Bacteria (CC4CARB)</b>	Elliott Pauli, RTI International

<b>No.</b>	<b>Title</b>	<b>Corresponding Author</b>
35	<b>How GARDP's REVIVE platform is providing open-access tools and resources for the antimicrobial R&amp;D community</b>	<b>Astrid Pentz-Murr</b> , GARDP
36	<b>The human microbiome as source and target for new antibacterial compounds</b>	<b>Andreas Peschel</b> , University of Tübingen
37	<b>The Swiss Round Table on Antibiotics fosters the development and availability of antibiotics</b>	<b>Barbara Polek</b> , Round Table on Antibiotics
38	<b>Use of Sub-Cellular Fluctuation Imaging (SCFI) for real-time monitoring of antibiotic resistance in <i>N. gonorrhoeae</i></b>	<b>James Preece</b> , FluoretiQ Ltd
39	<b>VERI-5.: a compact hardware and single use cartridge system for rapid detection of Urinary Tract Infections</b>	<b>James Preece</b> , FluoretiQ Ltd
40	<b>Self-adjuvant nanovaccination as novel tool to combat bacterial infections</b>	<b>Oliver Reimann</b> , Belyntic GmbH
41	<b>Highly-neutralizing anti-PcrV antibodies as clinical candidates against <i>Pseudomonas aeruginosa</i></b>	<b>Jan Rybniker</b> , Center for Molecular Medicine Cologne
42	<b>Turning enzymes into efficient enzymiotics</b>	<b>Izabela Sabala</b> , Mossakowski Medical Research Institute PAS
43	<b>Microbialbiosensor for industrial online analysis</b>	<b>Tobias Schröter</b> , FluIDect GmbH
44	<b>Development of a Synthetic Human Urine formulation for the study of uropathogenic <i>E. coli</i> (UPEC) physiology and the discovery of antibiotics</b>	<b>Benjamin Sellner</b> , University of Basel
45	<b>Retrospective analysis of cefiderocol for treating severe drug-resistant gram negative bacterial infections</b>	<b>Leeanne Stewart</b> , Belfast Health And Social Care Trust
46	<b>Exploring Challenges in Vaccine Development for Emerging Pathogens: A Study of Regulatory Interactions between Developers and Regulators</b>	<b>Igor Stojkov</b> , Paul-Ehrlich-Institute
47	<b>New Generation Antimicrobials Developed Using Efflux Resistance Breaker (ERB) Technology</b>	<b>Mark Sutton</b> , UK Health Security Agency
48	<b>An in vivo-like lung infection model for pharmacokinetics and –dynamics studies</b>	<b>Leoni Swart</b> , University of Basel
49	<b>MptB inhibitors increase the efficacy of antibiotics reducing intracellular burden for <i>Mycobacterium tuberculosis</i> and nontuberculous <i>Mycobacterium avium</i></b>	<b>Lydia Taberner</b> , University of Manchester
50	<b>Search for the new generation of the antifungal drugs based on the polyene antibiotics</b>	<b>Anna Tevyashova</b> , Constructor University
51	<b>Human urothelial microtissue model for in vitro studies of urinary tract infection and its treatment</b>	<b>Lisette van Os</b> , University of Basel

No.	Title	Corresponding Author
52	<b>New bioluminescent preclinical infection mouse models using recently isolated strain of multi drug resistant KAPE bacteria</b>	<b>Marc Vandamme</b> , Voxcan
53	<b>Next Generation Assay Optimisation for Drug Screening Using design of experiments and automation for antibiotic adjuvant discovery</b>	<b>Adam Winnifrith</b> , University of Oxford
54	<b>Acceleration of Hit-to-Lead Drug Development by Nanoliter-scale Screening of Mutasynthetic BamA Inhibitor Library</b>	<b>Zerlina Wuisan</b> , University of Giessen
55	<b>BTZ-043 shows good safety and strong bactericidal activity in a seamless phase 1b/2a study in patients with pulmonary TB</b>	<b>Julia Dreisbach</b> , University Hospital Munich
56	<b>Granulytics: Antimicrobial protein-lipid complexes derived from the human immune peptides to tackle Antimicrobial resistance</b>	<b>Owais Hameed</b> , Université de Fribourg
57	<b>High-throughput sequencing technologies for genome methylation analysis and possible epigenetic intervention strategies in the model bacterium Helicobacter pylori</b>	<b>Christine Josenhans</b> , Ludwig Maximilian University Munich
58	<b>Novel thiopeptides to target intractable bacterial infections</b>	<b>Clovis Shyaka</b> , A&J Science
59	<b>From Stress to Adaptive Success: A systematic investigation of physiological adaptation of Escherichia coli facing harsh environments</b>	<b>Alexandra Evelyne Huber</b> , University of Basel
60	<b>Combining growth inhibition assays and metabolic profiling to accelerate discovery of antibiotics with unconventional modes of action</b>	<b>Sebastián Sosa-Carrillo</b> , University of Basel

### The pre-scheduled one-to-one meetings take place as follows:

Day 1, 6 March: 10:00 - 19:00

Day 2, 7 March: 08:30 - 18:00

The length of each meeting slot is 30 minutes. Please check your individual meeting schedule for times and locations of your confirmed meetings.

**Meeting locations:** Exhibition Hall

Need help? Please see the Partnering Help Desk at the registration.

# Thank you to our sponsors, exhibitors and partners

## Local Host



## Platinum Sponsors



## Gold Sponsors



## Silver Sponsors



## Bronze Sponsors



## Supporting Partners



## Room for your notes

## Room for your notes



The

# 9<sup>th</sup> AMR Conference

Novel Antimicrobials & AMR Diagnostics

will return to the Congress  
Center Basel in **March 2025**

**Stay tuned for updates**

[amr-conference.com](https://amr-conference.com)  
[#AMRconference](https://twitter.com/AMRconference)

